Prostate Cancer Upgrading Reference Set

Description

Research repository designed to establish prostate cancer upgrading reference set and development of a risk prediction tool. Repository will include clinical information and biologics on a cohort of 240 men, to predict presence of high grade cancer at time of prostatectomy (removal of prostate) among patients with a low grade cancer diagnosis at time of biopsy.

Conditions

Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Research repository designed to establish prostate cancer upgrading reference set and development of a risk prediction tool. Repository will include clinical information and biologics on a cohort of 240 men, to predict presence of high grade cancer at time of prostatectomy (removal of prostate) among patients with a low grade cancer diagnosis at time of biopsy.

Biomarkers and Clinical Parameters Associated With Gleason Score Upgrading

Prostate Cancer Upgrading Reference Set

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

San Antonio

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Prostate cancer, confirmed on prostate biopsy, within two years of scheduled radical prostatectomy.
  • 2. Prostate cancer must be graded as Gleason 3+3 on the biopsy immediately prior to radical prostatectomy. (Secondary eligibility will be established on central review of pathology slides, and blocks if available, at Cornell Central Pathology Laboratory to confirm eligibility.)
  • 3. Prostate cancer may have been detected on prior biopsy as well but must not be greater than Gleason 3+3. (Also requires Central Pathology Laboratory review.)
  • 4. Slides must be available for Central Pathology Laboratory review on any biopsy showing prostate cancer. FFPE Blocks may also be requested if available.
  • 5. Patient must have selected radical prostatectomy as treatment for prostate cancer.
  • 6. Signed informed consent.
  • 7. Blocks and/or slides from prostate biopsy and from radical prostatectomy must be available for analysis by Central Pathology laboratory.
  • 8. Willingness to provide long-term follow-up information regarding additional treatments and cancer status.
  • 9. Willingness to provide blood and urine specimens prior to radical prostatectomy for placement in the EDRN Upgrading Reference Set repository.
  • 10. Willingness to provide demographic and clinical information related to prostate cancer and prostate cancer risk (e.g., race/ethnicity, family history of prostate cancer).
  • 1. Gleason score greater than 3+3 on any prior prostate biopsy.
  • 2. Any treatment other than radical prostatectomy planned for prostate cancer.
  • 3. Prior treatment of the prostate with androgen deprivation, radiation, or other cytotoxic chemotherapy.

Ages Eligible for Study

35 Years to 99 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

The University of Texas Health Science Center at San Antonio,

Ian M Thompson Jr, MD, PRINCIPAL_INVESTIGATOR, University of Texas

Study Record Dates

2025-12